Original title: Jiu’an Medical was asked whether it caters to the hot speculation stock price after closing eight consecutive daily limit
Jiu’an Medical, whose share price has soared after an announcement was made two weeks ago, received a letter of concern from the Shenzhen Stock Exchange on the evening of November 23, and was asked about the relevant information about the kit product disclosed in the aforementioned announcement and whether there is a share price that caters to hot speculation. On the 24th, Jiu’an Medical once again went out of its daily limit and closed at 14.60 yuan. Flush data shows that the company has closed eight consecutive daily limits from November 15 to 24, and its stock price has risen by 114.71%.
On November 8, Jiu’an Medical disclosed the “Announcement on the Company’s Subsidiary’s New Coronary Antigen Home Self-Testing OTC Kits Obtained US FDA EUA Authorization” (hereinafter referred to as the “Authorization Announcement”). It was learned early in the morning that its U.S. subsidiary iHealth Labs Inc.’s product new coronavirus antigen home self-testing OTC kit has been authorized by the U.S. Food and Drug Administration for emergency use. It can be used in the U.S. and recognized by the U.S. EUA during the U.S. public health and health emergency. Sales in the country or region, it is expected that it may bring related sales revenue to the company in the future. The announcement also pointed out that the company is currently unable to predict the future impact of the product on the company’s operating income and performance.
At the same time, Jiu’an Medical recently responded to investors’ questions on the above-mentioned issues on the interactive Yi platform, saying that “the kit has been sold locally to both the C-end and the B-end.” The official website of the kit is sold at a price of $6.99 (1 “The kit product belongs to the product category of the US federal government’s centralized procurement” “The kit has begun mass production and is sold locally” “The current monthly production capacity is 100 million copies” “The plan is to increase production capacity by the beginning of 2022 To 200 million servings per month”.
The letter of concern requires Jiu’an Medical to combine factors such as the emergency use authorization period, market demand, selling price, capacity and capacity expansion plans, production and sales, market share, competitive products, profitability and other factors of the kit products, indicating that the company is on the interactive platform Whether the replies related to the kit products are prudent and objective, whether they have factual basis and are consistent with the actual situation, whether there are misleading statements or publicity, advertisements, or exaggerated statements; explain the company’s relevant information on the kit products on the interactive platform State whether it is a major event or the progress of a major event as required by the “Stock Listing Rules (Revised in 2020)” and the basis for judgment. If so, further explain why the “Authorized Announcement” and “Announcement of Abnormal Stock Trading Fluctuations” did not disclose the foregoing circumstances And compliance; the self-inspected company’s recent media interviews, institutional and investor surveys, and response to investor inquiries, etc., explain whether there is any violation of the accuracy, timeliness, and fairness of information disclosure, and whether there is any use of interactive easy The platform caters to market hotspots and hype about company stock prices.
From the perspective of financial status, Jiu’an Medical performed poorly during the year. The third quarter report shows that the company achieved operating income of 790 million yuan in the first three quarters, a year-on-year decrease of 50.82%; realized net profit attributable to shareholders of listed companies of 50.128 million yuan, a year-on-year decrease of 86.19%. Among them, operating income in the third quarter was 221 million yuan, down 60.93% year-on-year; net profit was a loss of 4.649 million yuan, down 104.41% year-on-year. Prior to this surge, its stock price has shown a turbulent downward trend this year. From January 4 to November 12, it fell by 25.84%, and hit a new low of 5.80 yuan in intraday trading on October 28.
.